Donate

News

Illustration for article: Fulvio Mavilio, expert in gene therapy for rare diseases, Généthon's new Scientific Director

Fulvio Mavilio, expert in gene therapy for rare diseases, Généthon's new Scientific Director

Fulvio Mavilio, PhD (aged 58), an international acknowledged expert and pioneer in gene therapy for rare diseases for more than twenty years, was appointed as the new Scientific Director of Généthon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (AFM) with donations from France's annual Telethon) on January 1st, 2012.
Illustration for article: Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C

Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C

The results of a Phase I clinical trial of gene therapy for limb-girdle muscular dystrophy type 2C (a rare neuromuscular disease) have just been published in the journal Brain on January 11, 2012.
Illustration for article: Resources in 2014

Resources in 2014

In 2014, the total resources of the French Muscular Dystrophy Association (AFM) totalled €111.2 million, €92.9 million - 83.5% - of which came from the Telethon.
Illustration for article: Key figures: €35.1 million for patient assistance

Key figures: €35.1 million for patient assistance

Helping patients is a prime concern for the French Muscular Dystrophy Association (AFM). In 2011, AFM allocated at least €35.1 million to this mission.
Illustration for article: Key figures: €60.6 million to cure rare diseases

Key figures: €60.6 million to cure rare diseases

In 2015, thanks to Telethon donations, the French Muscular Dystrophy Association (AFM-Téléthon) invested € 63.8 million in rare disease research. Every year, it devotes about two-thirds of its missions budget to this prime concern.